A biopharmaceutical firm involved in the discovery.

Michael T. Flavin, chief executive officer of Advanced Lifestyle Sciences. ‘We look forward to advancing selected substances into preclinical development also to sharing these results with potential corporate companions.’.. Advanced Life Sciences scientific publication demonstrates triterpenoids’ potential since anticancer agents Advanced Life Sciences Holdings, Inc. , a biopharmaceutical firm involved in the discovery, commercialization and advancement of novel drugs in the therapeutic areas of infection, and respiratory diseases oncology, today announced the publication of a study paper in the journal Bioorganic and Medicinal Chemistry Letters that reviews data using the business’s core triterpenoid platform technology in the discovery and development of new tumor therapeutic agents.Scientists at Advanced Life Sciences have got identified a novel class of proprietary triterpenoids that cause cell loss of life predominantly via the induction of apoptosis, which is a highly regulated process where excessive or harmful cells are eliminated in order to maintain regular cell development and cells homeostasis..

AGA Research Foundation receives grant for gastroenterology research Today, the American Gastroenterological Association announced that Takeda Pharmaceuticals U.S.A., Inc. Will provide a $1.5 million unrestricted grant to the AGA Research Foundation endowment. This grant to the AGA Research Foundation endowment funds research and discoveries in gastroenterology, and supports youthful investigators over the United States. The AGA Research Foundation provides research grants to investigators in hepatology and gastroenterology. The basis's grants transform young experts' lives by encouraging them to embark on and continue careers in research.